615 related articles for article (PubMed ID: 29052442)
1. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of RANK ligand to treat bone metastases].
Body JJ
Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
4. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
6. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
7. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
9. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
10. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
11. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
Body JJ; Gatta F; De Cock E; Tao S; Kritikou P; Wimberger P; Mebis J; Peeters M; Pedrazzoli P; Caraceni A; Adamo V; Hechmati G
Support Care Cancer; 2017 Sep; 25(9):2823-2832. PubMed ID: 28429148
[TBL] [Abstract][Full Text] [Related]
12. [Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
Abe M; Miki H; Nakamura S
Rinsho Ketsueki; 2015 Aug; 56(8):997-1004. PubMed ID: 26345558
[TBL] [Abstract][Full Text] [Related]
13. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
14. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Raje N; Vadhan-Raj S; Willenbacher W; Terpos E; Hungria V; Spencer A; Alexeeva Y; Facon T; Stewart AK; Feng A; Braun A; Balakumaran A; Roodman GD
Blood Cancer J; 2016 Jan; 6(1):e378. PubMed ID: 26745852
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches for protecting bone health in patients with breast cancer.
Lüftner D; Niepel D; Steger GG
Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
[TBL] [Abstract][Full Text] [Related]
18. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
19. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
